Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk defends disappointing next gen obesity drug: 'It will be an important product' NBC10 Philadelphia Two Weeks on GHK CU by Rory Uphold The Ladies Room Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet